Rexahn: Corporate Presentation (Rexahn Pharmaceuticals, Inc) - Jul 2, 2015 - Anticipated initial combination safety data from P2a trial (NCT02089334) in combination with Afinitor for metastatic renal cell carcinoma in mid-2015
Anticipated P2a data • Oncology • Renal Cell Carcinoma
|